Skip to content

Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc.

Petition for certiorari denied on January 13, 2020

Docket No. Argument Opinion Vote Author Term
18-817 N/A N/A N/A N/A OT 2019

Issue: Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps. CVSG 12/6/2019.

SCOTUSblog Coverage

DateProceedings and Orders (key to color coding)
10/26/2018Application (18A461) to extend the time to file a petition for a writ of certiorari from November 12, 2018 to December 27, 2018, submitted to The Chief Justice.
10/31/2018Application (18A461) granted by The Chief Justice extending the time to file until December 27, 2018.
12/27/2018Petition for a writ of certiorari filed. (Response due January 28, 2019)
01/22/2019Motion to extend the time to file a response from January 28, 2019 to February 12, 2019, submitted to The Clerk.
01/23/2019Motion to extend the time to file a response is granted and the time is extended to and including February 12, 2019.
01/28/2019Brief amici curiae of Intellectual Property and Innovation Professors, Engine Advocacy, et al. filed.
01/28/2019Brief amici curiae of The Association for Accessible Medicines and Certain Individual Companies filed.
02/12/2019Brief of respondent Vanda Pharmaceuticals USA, Inc. in opposition filed.
02/26/2019Reply of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
02/27/2019DISTRIBUTED for Conference of 3/15/2019.
03/15/2019Letter of Hikma Pharmaceuticals USA Inc., et al. received.
03/18/2019The Solicitor General is invited to file a brief in this case expressing the views of the United States.
05/22/2019Amendment to Rule 29.6 Corporate Disclosure Statement filed with respect to brief in opposition of respondent Vanda Pharmaceuticals Inc.
12/06/2019Brief amicus curiae of United States filed.
12/20/2019Supplemental brief of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
12/23/2019DISTRIBUTED for Conference of 1/10/2020.
12/23/2019Supplemental brief of respondent Vanda Pharmaceuticals USA, Inc. filed. (Distributed)
12/26/2019Letter of December 26, 2019 from counsel for petitioner received. (Distributed)
01/13/2020Petition DENIED.